Anteris names Susan Knight and Stephen Denaro as PARADIGM trial advances with higher Q1 burn
Anteris appointed industry veterans Susan Knight and Stephen Denaro to its board to bolster its heart valve development strategy. The company advanced its PARADIGM clinical trial and reported a higher Q1 cash burn as it ramps commercialisation efforts.
1. Board Appointments Enhance Strategy
Anteris expanded its governance team by adding Susan Knight and Stephen Denaro to its board, aiming to leverage their expertise in cardiovascular device development and commercial execution to support the company’s next-generation heart valve strategy.
2. PARADIGM Trial Progress and Cash Burn
The company advanced its PARADIGM clinical trial for its proprietary valve platform while Q1 cash burn increased, reflecting intensified investments in manufacturing scale-up, regulatory preparations and market launch readiness.
Related News
NVDA
Nvidia Raises July Quarter Guidance, Forecasts $91B Fiscal 2027 Revenue
NVDA•
GOOG
Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027
GOOG•
ELF
Elf Beauty Q4 Sales Jump 35% to $449.3M, Forecasts Lower FY27 Sales
ELF•
TJX
TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch
TJX•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
Sources
FF